Table III.
Multivariate logistic regression models to examine the effect according to sex and age distribution
| Outcome | Subgroup | CMV disease | No. | Events | Total f/u duration [years] | IR* | Odds ratio (95% CI) | P-value for interaction | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Model 1 | Model 2 | Model 3 | Model 4 | ||||||||
| MI | Sex: | 0.962 | |||||||||
| Male | No | 3680 | 33 | 11945 | 2.76 | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | ||
| Yes | 368 | 7 | 1142 | 6.13 | 2.22 (0.90–4.72) | 2.23 (0.90–4.74) | 2.26 (0.92–4.81) | 2.30 (0.96–5.49) | |||
| Female | No | 2990 | 16 | 9699 | 1.65 | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | ||
| Yes | 299 | 3 | 906 | 3.31 | 1.99 (0.46–5.98) | 2.14 (0.50–6.44) | 2.13 (0.49–6.40) | 1.73 (0.40–7.52) | |||
| Age [years]: | – | ||||||||||
| 20–39 | No | 1650 | 2 | 5695 | 0.35 | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | ||
| Yes | 165 | 0 | 557 | 0.00 | – | – | – | – | |||
| 40–64 | No | 3810 | 23 | 12474 | 1.84 | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | ||
| Yes | 381 | 6 | 1182 | 5.07 | 2.79 (1.03–6.43) | 2.80 (1.04–6.46) | 2.77 (1.02–6.39) | 2.58 (0.89–7.51) | |||
| ≥ 65 | No | 1210 | 24 | 3476 | 6.91 | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | ||
| Yes | 121 | 4 | 307 | 12.99 | 1.86 (0.55–4.82) | 1.87 (0.55–4.85) | 1.81 (0.53–4.70) | 1.95 (0.68–5.64) | |||
| CHF | Sex: | 0.565 | |||||||||
| Male | No | 3680 | 27 | 11982 | 2.25 | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | ||
| Yes | 368 | 8 | 1139 | 7.02 | 3.11 (1.32–6.55) | 3.14 (1.33–6.59) | 3.08 (1.30–6.48) | 3.37 (1.46–7.76) | |||
| Female | No | 2990 | 25 | 9700 | 2.58 | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | ||
| Yes | 299 | 9 | 900 | 10.00 | 3.85 (1.70–7.95) | 4.21 (1.86–8.71) | 4.34 (1.91–9.01) | 4.17 (1.80–9.67) | |||
| Age [years]: | 0.029 | ||||||||||
| 20–39 | No | 1650 | 5 | 5693 | 0.88 | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | ||
| Yes | 165 | 2 | 553 | 3.62 | 4.08 (0.59–18.93) | 4.08 (0.58–18.91) | 4.76 (0.68–22.39) | 5.15 (0.57–46.51) | |||
| 40–64 | No | 3810 | 16 | 12488 | 1.28 | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | ||
| Yes | 381 | 11 | 1176 | 9.35 | 7.29 (3.29–15.57) | 7.47 (3.37–15.95) | 7.77 (3.50–16.63) | 9.40 (4.12–21.44) | |||
| ≥ 65 | No | 1210 | 31 | 3500 | 8.86 | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | ||
| Yes | 121 | 4 | 310 | 12.88 | 1.46 (0.44–3.70) | 1.49 (0.44–3.76) | 1.59 (0.47–4.03) | 1.66 (0.59–4.73) | |||
| AF | Sex | 0.448 | |||||||||
| Male | No | 3680 | 32 | 11921 | 2.68 | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | ||
| Yes | 368 | 4 | 1145 | 3.49 | 1.30 (0.39–3.26) | 1.32 (0.39–3.32) | 1.32 (0.39–3.33) | 1.64 (0.58–4.64) | |||
| Female | No | 2990 | 26 | 9685 | 2.69 | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | ||
| Yes | 299 | 5 | 902 | 5.54 | 2.05 (0.70–4.92) | 2.21 (0.75–5.30) | 2.29 (0.77–5.50) | 2.38 (0.83–6.80) | |||
| Age, years | 0.777 | ||||||||||
| 20–39 | No | 1650 | 4 | 5691 | 0.70 | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | ||
| Yes | 165 | 1 | 556 | 1.80 | 2.56 (0.13–17.28) | 2.56 (0.13–17.28) | 2.54 (0.13–17.21) | 1.25 (0.03–46.59) | |||
| 40–64 | No | 3810 | 28 | 12437 | 2.25 | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | ||
| Yes | 381 | 3 | 1188 | 2.52 | 1.11 (0.27–3.14) | 1.12 (0.27–3.17) | 1.11 (0.27–3.14) | 1.52 (0.46–5.02) | |||
| ≥ 65 | No | 1210 | 26 | 3477 | 7.48 | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | ||
| Yes | 121 | 5 | 303 | 16.50 | 2.18 (0.74–5.23) | 2.21 (0.75–5.28) | 2.17 (0.73–5.19) | 2.34 (0.90–6.09) | |||
Model 1 – non-adjusted, Model 2 – age- and sex-adjusted, Model 3 – age-, sex-, low income status-, type 2 NIDDM-, hypertension- and dyslipidemia-adjusted, Model 4 –age-, sex-, low income status-, type 2 NIDDM-, hypertension-, dyslipidemia-, SOT- and HSCT-adjusted.
*
per 1,000 patients. AF – atrial fibrillation, CHF – congestive heart failure, CI – confidence interval, CMV – cytomegalovirus, f/u – follow-up, HSCT – hematopoietic stem cell transplantation, IR – incidence rate, MI – myocardial infarction, NIDDM – non-insulin dependent diabetes mellitus, No. – number, Ref. – reference, SOT – solid organ transplantation.